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Introduction
Evidence is scarce about the eff ect of choice of contraceptive method on increased uptake of methods; however, a systematic review 1 in 2006 supported the theory that increased contraceptive choice for women is associated with increased uptake and better health outcomes (eg, lower pregnancy rates and fewer sexually transmitted infections [STIs] ). Furthermore, women continue use of their chosen contraceptives to a greater degree than do those who are denied a choice. 2 The female condom is a barrier method that could increase choice for women worldwide. Although distribution of female condoms continues to increase worldwide, doubling from 25 million to 50 million units between 2007 and 2010, it is substantially lower than that for male condoms, and accounts for only 0·19% of global condom procurement. 3 In 2011, the female condom was identifi ed by the Reproductive Health Supplies Coalition as one of several underused reproductive health technologies that could expand choice in reproductive health and family planning programmes, add value to the method mix, and respond to the needs of various clients.
than that for male condoms. This diff erence was compounded by the absence, until 2011, of an international standard to verify the quality of new devices. To secure regulatory approvals, including WHO-UNFPA prequalifi cation, manufacturers need to do clinical studies to verify the performance of new designs of female condoms. In 2009, the US FDA approved the second-generation female condom (FC2) on the basis of results of a non-inferiority study 6 in which the investigators compared the functional performance of FC2 with that of FC1 with respect to condom failure events. Studies of the functional performance of condoms typically collect detailed data for small numbers of condom uses (fi ve to ten uses) in a short period of time (4-6 weeks). Conversely, studies of condom eff ectiveness for prevention of pregnancy should be done over at least a 6 month period and are far more costly to do than are functional performance studies. Studies of contraceptive eff ectiveness were not needed for US FDA approval for FC2 and no studies of contraceptive eff ectiveness have been published for FC2. If new female condoms are noninferior to FC2 in function, choices will increase and individual needs can be considered for women wanting to prevent pregnancy and STIs and HIV. We assessed the functional performance and safety of three new female condom designs: the Woman's Condom, the VA worn-ofwomen (wow) Condom Feminine, and the Cupid female condom versus the FC2 device.
Methods

Study design and participants
We undertook this four-period, randomised, noninferiority, crossover, clinical trial between May 1, 2011, and Jan 31, 2012, at three centres in Shanghai, China (the Shanghai Institute of Planned Parenthood Research Hospital and two affi liated family planning districtsXuJiahui and Xuhui), and one centre in Durban, South Africa (an urban reproductive health clinic). Participants aged 18-45 years who were sexually active, monogamous, and not practising sex workers, were eligible for inclusion if they had no known allergies to the study products (latex, synthetic latex, polyurethane); used a reliable, nonbarrier method of contraception; and had no STIs (as established by pelvic examination and use of a syndromic diagnostic approach). Participants could be novice or experienced users of condoms, but had to be literate because take-home condom logs were used to obtain data. We excluded pregnant women (established by urine The numbers of women withdrawing after period one were two for the sequence CWVF, three for FVWC, none for VCFW, and three for WFCV; after period two were three, two, one, and two, respectively; and for period three were three, two, one, and two, respectively. C=Cupid. W=Woman's Condom. V=VA worn-of-women. F=second-generation female condom (FC2). Male partners were informed of the study through use of a fact sheet, which explained the purpose of the study and provided information about the study products and their role in the research. Our study methods are based on the recommendations of WHO-UNFPA. 
Randomisation and masking
We used a computer-generated randomisation sequence (SAS version 9.3 8 ) to assign patients to one of 12 sequences of condom use (fi gure 1). Randomisation was stratifi ed by site. We used a Williams design, which consisted of the random construction of a Williams square (fi rst step) and the random allocation of women to the treatment sequences, independently at each site (second step). 9 These sequences were balanced for period and treatment, and each treatment had a diff erent preceding treatment. To ensure such balance, the Williams design uses block sizes of four in a Latin square.
To devise a simple and eff ective method of concealment, we designed a scratch card per participant, containing the allocated treatment sequence, whereby each code for a given condom type was concealed beneath a separate foil square. For each card, research staff would remove (scratch) the foil corresponding to the visit number printed above the square, thereby revealing the next visit allocation in the sequence. This novel adaption of an existing technology had not been previously reported for concealment of the allocation sequence in a randomised crossover trial. The development and use of the cards for this trial has been reported elsewhere. 10 Participants were not masked to condom type because the designs are all quite distinct and required product-specifi c training.
Procedures
Our primary objective was to compare the functional performance of the four types of female condom within the selected study populations (fi gure 2). The FC2 was the control device, because the predicate device (FC1) ceased production in 2009. Each condom product was shipped by the manufacturer to Family Health International (now FHI 360) for quality assurance testing to ensure that products were of the quality specifi ed by 
The VA wow Condom Feminine
The VA wow condom (Medtech Products, India) is made of natural rubber latex and encases a medical-grade sponge at the closed end. The sponge is used for insertion and the outer anchoring structure has a triangular-shaped frame. The condom is lubricated with silicone oil. The device carries the CE Mark of the EU, and has approvals from the India Drug Control Authority and the Ministry of Health in Brazil.
The Cupid female condom
The Cupid condom (Cupid, India), manufactured in India, is available in some European and African countries. Made of natural rubber latex, the condom has an octagonal outer frame and is inserted with a medicalgrade sponge, which also holds the condom in place during use. The device is pre-lubricated with silicone oil and comes in natural latex and pink colours. The Cupid condom is the only scented condom of all those assessed. The condom holds the CE Mark of the EU, is prequalified by WHO-UN Population Fund and registered by the India Drug Control Authority. The primary endpoints were self-reported total clinical failure and total female condom failure. Additionally, we assessed the component failure events of clinical breakage, non-clinical breakage, total breakage, slippage, misdirection, and invagination.
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Panel 1 shows the defi nitions of each failure mode analysed. We also collected data for safety and acceptability. Failure events are recognised by WHO and other regulatory agencies.
Our secondary objectives were to assess the safety and acceptability of each condom type and to compare acceptability endpoints between the four types, with superiority hypotheses. We measured and assessed safety of each device according to number, severity, relatedness, and duration of adverse events. We collected standard acceptability measures and these data will be reported elsewhere.
In this study, each woman was asked to use fi ve of each of the four condom types and to complete a condom log at home after each condom use. After women completed use of each condom type, they returned to the clinic to be interviewed about their experiences. Condom logs were used to obtain data for condom function and safety. We used interviewer-assisted questionnaires to gather acceptability and preference data.
Statistical analysis
We calculated the power to show non-inferiority obtained for diff erent sample sizes, starting with a minimum of 200 couples completing the study as recommended by ISO 25841-2011 for functionality studies of acute failure events with female condoms based on self-reports. 12 We assumed a total failure rate of 4% for FC2 as reported from previous research, 6 and a correlation between uses of 0·15, as reported for male condoms. 13 With 3% as a clinically determined margin of non-inferiority and a signifi cance level of 5% for the hypothesis of non-inferiority, 500 women (250 per country) completing the study would provide 98% power in each country. We expected a non-completion rate of 15% (ie, 85% would provide relevant follow-up data for at least one condom of each type); therefore, we increased the sample size to 600 women (300 per country). In the power calculation, we adjusted for various comparisons with the Bonferroni criterion. 14 The hypothesis for the primary endpoints of total clinical failure and total female condom failure and their component failure events, was that each of the three new condoms was non-inferior to FC2 for the rate of events within a margin of 3·0%.
The main analysis for primary and secondary endpoints was according to the assigned condom use sequence in the subset of participants who provided relevant follow-up data for at least one condom of each type (per-protocol analysis). We did an additional analysis with women with complete or incomplete condom series (one to four condom types, one to fi ve uses each; data not shown). This additional analysis was by intention to treat, but with exclusion of three participants for whom no data about condom function were available. All analyses were stratifi ed by country.
To show non-inferiority, the upper limit of the two-sided 90% CI for the diff erence in the occurrence of events (new condom minus FC2) needed to be below 3·0%. If noninferiority was shown, we tested superiority at a 5% level of signifi cance using a two-sided 95% CI.
We analysed primary endpoints with a generalised estimating equation approach assuming a binomial distribution, and with an identity link function, including type of condom in the model at the couple-use level and defi ning couples as clusters, to take into account the crossover nature of the design. We used an interchangeable error structure within couples and adjusted results by multiplicity with Scheff é's method. 13 This trial is registered, number DOH-27-0113-4271.
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writ ing of the report. MEB, GP, JP, RG, and CJ had full access to the primary data. All other authors (JAS, JW, YZha, and YZho) had access to the data collected in their own country. All authors had fi nal responsibility for the publication. Figure 1 shows the trial profi le. 600 women were enrolled in the study (300 per country). 572 (95%) women completed the study with each woman using at least one condom of each of the four types. These women comprise the main analysis population. Only three women, in South Africa, did not use any condom. Chinese participants were older than participants from South Africa (table 1) . Women in both countries were well educated, with 72% in China and 90% in South Africa having more than 10 years of schooling (table 1) . Most Chinese participants were married or living with their partners, whereas most South African participants were not married or residing with their partners (table 1) . 188 (63%) of 300 Chinese participants and 272 (100%) of South African participants had used male condoms previously, whereas 39 (14%) of South African women had previous experience with female condoms compared with no participants in China.
Results
11 350 female condoms were used in this study by women in the main analysis population (2838 Cupid, 2850 FC2, 2827 VA wow. and 2835 Women's Condoms). Table 2 shows the mean failure rate and failure diff erence of Cupid, VA wow, and Woman's Condom compared with FC2 for both countries combined. Non-inferiority was shown, within the non-inferiority margin, for all failure modes for the three new devices versus FC2 (data not shown) and for the two countries combined (table 2 and fi gure 3). The additional analysis done with women with complete or incomplete condom series provided similar results (data not shown).
We noted no evidence of superiority for any of the new condoms compared with FC2 in any of the failure modes (table 2) .
Overall, the occurrence of adverse events and medical problems for the enrolled population was low (data not shown). Only two (<1%) participants in South Africa reported serious adverse events, unrelated to use of the study products. 27 (5%) adverse events were reported in the 597 women using at least one condom at least once. Adverse events occurred in fewer than 1% (range 0·14-0·38%) of participants for each condom type. Adverse event reports were vaginal burning (fi ve with VA wow in China); vaginal itching (one with Cupid, one with FC2, and one with Women's Condom in South Africa); 
Discussion
Although individual failure rates vary by country and condom type, the three new devices assessed in this study were non-inferior to the reference condom (FC2) within the non-inferiority margin for all the functional parameters. The rates of total clinical failure, total female condom failure, and component failure reported were expected and are consistent with fi ndings from previous, similarly undertaken studies. 6, [15] [16] [17] Furthermore, the failure results reported in this study were from two culturally diverse study populations. That the results are similar between South Africa and China attests further to the validity of the fi ndings. These data show that clinically, the new female condoms assessed function in a similar way to the FC2. Data from this study have been used to fi nalise the dossier submitted to WHO-UNFPA for the Cupid condom and resulted in its prequalifi cation for public sector procurement in June, 2012. 18 The manufacturer of the Woman's Condom (Dahua, China) will use these data to fi nalise their dossier and submissions to WHO-UNFPA and US FDA. The VA wow condom is under review by WHO-UNFPA; however, manufacture of the product is suspended, possibly related to change of ownership of the factory.
On the basis of fi ndings from this trial, these new female condoms could be important players in contraception and STI prevention. The availability of new types of female condoms will provide donors and users with more options and could reduce the unit price of devices. 4 Although prediction of how far the price of female condoms will reduce in the future is not possible, the Reproductive Health Supplies Coalition has published information comparing diff erent unit costs to the donor funded public sector, indicating that the Cupid female condom, which was prequalifi ed in 2012, will be sold at a lower price per unit than FC2. 4 However, studies of contraceptive eff ectiveness and those showing eff ectiveness or reductions in STI incidence with these new female condoms are still needed.
Contraception is one strategy that can have an eff ect on and improve maternal health by reducing unplanned pregnancy. In 2009, estimates showed that if all women who wanted to avoid pregnancy used modern contraceptives, the number of unintended pregnancies in developing countries would fall from 75 million to 22 million annually. 19 Reasons for unmet need for contraception go beyond simple access to methods, and are attributable to a combination of factors including personal and cultural issues, religious restrictions, concern about side-eff ects, health concerns, and scarcity of knowledge. For this reason, the need to have a range of available contraceptive methods is crucial (panel 2).
A limitation of our study was that masking of the participants and research staff to the products was not possible because the products all diff er in appearance. We used allocation concealment to ensure that this limitation was minimised. This study was based on only self-reported measures of condom use. Reporting of condom use by participants can be inaccurate compared with more reliable methods such as exposure to prostatespecifi c antigen, which provides a more objective 
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Panel 2: Research in context
Systematic review
We searched PubMed between Jan, 2000, and Oct, 2012, for articles published up to November, 2012, with the search terms "female condom functional performance". No randomised trials, using any of the three new types of female condom-the Woman's Condom, the VA worn-of-women (wow) Condom Feminine, and Cupid-were identifi ed, aside from one randomised, non-inferiority trial 6 used to establish the functional performance of the second-generation female condom, FC2, compared with the predicate device (FC1).
Interpretation
This study is the fi rst randomised trial of the functionality of female condoms in China. The new female condoms were non-inferior to the reference condom (FC2) within a margin of 3% failure for all the functional parameters. This is the fi rst trial that has provided important function data for these devices and has been used to compile evidence for WHO-UNFPA prequalifi cation. Because of this trial, the Cupid condom has already been approved by WHO-UNFPA and is available for public sector procurement. Manufacturers of the other devices are using these data in their ongoing applications to regulatory authorities. Access to various types of female condoms could improve choice for women in need of a contraceptive method or of dual protection against pregnancy and infection.
